Hemodynamic Flow Alteration Devices Market is Segmented By Type (Embolic protection devices, Chronic total occlusion devices), By End-User (Hospitals, Clinics, Ambulatory Care Center, Home Care Setting, Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2023-2030.
Hemodynamic Flow Alteration Devices Market is Expected to reach at a CAGR of 8.7% during the forecast period (2023-2030). Hemodynamic flow alteration devices are used in treating peripheral vascular diseases which are caused by the formation of atherosclerotic plaques in arteries, which are responsible for the circulation of blood in various organs, the head, and the limbs. The rising prevalence of cardiac disorders and diabetes, rising demand for home-based and non-invasive monitoring systems, advances in technology, increasing funding from private players and government bodies, and an increase in the number of people suffering from hypertension are some of the factors driving the growth of the market.
Hemodynamic Flow Alteration Devices Market Statistics
|
Metrics |
Details |
|
Market CAGR |
8.7% |
|
Segments Covered |
By Type, By End-User, By Form, By Application, and By Region |
|
Report Insights Covered |
Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights. |
|
Fastest Growing Region |
Asia Pacific |
|
Largest Market Share |
North America |
Increasing R&D investments in the pharmaceuticals and biotechnology industry will drive the market growth
Neurosurgeons and other medical professionals are increasingly interested in therapeutic options that can effectively reduce the risk of fatality or severity of neurovascular diseases in patients. With an increasing number of patients suffering from neurovascular diseases (such as epilepsy, brain stroke, and cerebral aneurysm) and the severity of medical conditions (such as bleeding and local infections) in target patients, demand for effective neurovascular treatments is increasing across key markets such as the United States, Germany, Japan, China, and India. A cerebral aneurysm, for example, is a common neurovascular disorder all over the world. This condition is associated with a significant risk of bleeding or permanent neurological damage. In the United States, there will be 6.5 million brain aneurysm instances documented by 2020; additionally, 30,000 people will have a brain aneurysm rupture each year.
Demand for minimally invasive neurosurgery operations is on the rise. Minimally invasive medical procedures have several advantages over traditional surgical procedures, including a shorter hospital stay, faster patient recovery, increased procedural safety and efficacy, and lower costs. As a result, medical experts worldwide are becoming more accepting of endoscopic and other minimally invasive surgical methods. Geriatric patients are more vulnerable to neurovascular and neurological disorders. They choose treatment options that provide simple diagnosis, simple treatments, increased safety, the shortest possible hospital stay, improved efficacy, and acceptable costs.
Furthermore, aging rises the risk of thrombotic events such as pulmonary embolism, stroke, and epilepsy, all of which can necessitate neurosurgical surgery. Furthermore, arteriovenous malformations can cause hemorrhages and seizures, most common in those over the age of 40. (Source: Medscape). As a result, the growing elderly population and the need for minimally invasive procedures will likely provide considerable growth possibilities for both established and fledgling hemodynamic flow alteration devices companies.
Furthermore, patient awareness about coronary heart diseases and peripheral vascular disorders plays a vital role in market growth. Several educational, government and non-governmental organizations and key players have launched awareness programs to increase awareness about these diseases among patients, doctors, and healthcare providers. The impact of this factor currently influences the market growth in the emerging economies, as the adoption of advanced treatment devices is low in developing nations.
Various governments, particularly those in emerging economies, have boosted their spending on developing their healthcare infrastructure over the last decade. As a result, increased public and private investment in these regions' health infrastructure will boost the adoption of hemodynamic flow alteration devices in developing countries. This contributes to the growth of the global hemodynamic flow alteration devices market.
Risk involved in invasive procedures is likely to hamper the market growth
Apart from the discomfort of invasive monitoring (particularly the insertion of the pulmonary artery catheter), there are several risks associated with this technique, including sepsis, bleeding, cardiac arrhythmias, decreased circulation to the distal limb, bleeding, nerve damage (during insertion), thrombosis, air embolism, and pulmonary capillary necrosis. These factors increase the likelihood of death during invasive hemodynamic procedures. As a result, invasive hemodynamic flow alteration devices is only recommended for a few indications where the risks outweigh the benefits of obtaining the necessary data during the procedure. In addition, invasive hemodynamic flow alteration devices are not recommended for elderly or frail patients. Furthermore, invasive hemodynamic monitoring is prohibitively expensive and necessitates the insertion of catheters into patients by skilled professionals. Although invasive hemodynamic monitoring gives accurate, comprehensive, and continuous data on a patient's hemodynamic state, the above hazards limit its usage. Price regulations, competitive pricing, coverage and payment policies, technical assessments, and comparative effectiveness of therapies are other factors reducing healthcare-related costs. The lengthy regulatory authentication/validation process for developing providers is expected to stifle the growth of hemodynamic flow alteration devices market.
Hemodynamic Flow Alteration Devices Market Segment Analysis
The embolic protection devices segment is expected to grow at the fastest CAGR during the forecast period (2021-2028)
The hemodynamic flow alteration devices market is divided into embolic protection devices and chronic total occlusion devices. The embolic protection devices segment accounted for most of the hemodynamic flow alteration devices market in 2019. This is due to the advantages of EPDs over CTO devices, such as the ability to capture embolic debris while maintaining continuous blood flow. To prevent distal embolization, embolic protection devices (EPD) trap blood and luminal debris within the saphenous vein graft (SVG) during stenting. These devices are classified into three types: distal occlusion devices, distal filters, and proximal occlusion devices. By capturing and removing debris that may become dislodged during surgical procedures such as SVG interventions, percutaneous coronary intervention, aortic valve stenosis, and so on, these devices provide the most proven strategy for reducing periprocedural myocardial infarction (MI) and major adverse cardiovascular events. EPDs are critical in reducing complications caused by blockages in small blood vessels caused by debris in the bloodstream. They are a component of the most dependable, evidence-based procedure for lowering periprocedural MI and other major cardiovascular events.
The launch of new products are also boosting this segment. For instance, in October 2020, Keystone Heart Ltd., a Venus Medtech Company, received the European CE mark for the TriGUARD 3 Cerebral Embolic Protection (CEP) Device. It is designed and innovated to reduce the risk of cerebral damage by deflecting embolic debris away from the brain. This is done from cerebral circulation during Transcatheter Aortic Valve Implantation (TAVI) and other surgical transcatheter heart procedures.
Furthermore, Contego Medical, LLC received CE Mark for the new product Vanguard IEPa in April 2017. It is a Peripheral Balloon Angioplasty System with Integrated Embolic Protection. Furthermore, the company intends to market the product to endovascular specialists who perform lower limb angioplasty procedures in Europe. The system represents the most recent advancement in Contego's Integrated Embolic Protection (IEP) technology, incorporating a peripheral angioplasty balloon and a distal embolic filter on the same catheter.
Hemodynamic Flow Alteration Devices Market Geographical Analysis
North America region holds the largest market share of global hemodynamic flow alteration devices market
North America is expected to dominate the market in the forecast period. The rising prevalence of cardiovascular and neurovascular diseases in the region is a major factor driving the growth of the embolic protection devices market in the coming years. Obesity prevalence, lifestyle patterns, and unhealthy dietary habits will all have a positive impact on regional market growth. The strong presence of major industry players in North America will fuel the growth of the hemodynamic flow alteration devices industry.
Hemodynamic Flow Alteration Devices Market Competitive Landscape
The hemodynamic flow alteration devices market is highly competitive with presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include Abbott Laboratories, Medtronic, Boston Scientific, Cordis, Contego Medical, Claret Medical , BD, Biosensors International Group Ltd.
The market for hemodynamic monitoring is fiercely competitive, with several leading companies. Few big firms currently dominate the market in terms of market share. On the other hand, mid-size to smaller businesses are expanding their market presence by releasing new gadgets at lower rates, thanks to technical improvements and product innovations. For instance, in 2020, Cerenovus Stroke Solutions, a suite of three devices designed to assist physicians in clot removal procedures, was launched by Johnson & Johnson. Cerenovus Large Bore Catheter, Cerebase DA Guide Sheath, and Embotrap III Revascularization Device are among the devices.
Hemodynamic Flow Alteration Devices Market COVID-19 Impact Analysis
COVID-19 pandemic has impacted on every aspect of the medical device industry, including the market for hemodynamic flow alteration devices. Even though emergency and outpatient services are available in cardiology departments, the number of patient visits to hospitals has decreased significantly in the last six months. Patient visits have been significantly reduced due to nationwide lockdowns and social distancing measures. This has resulted in even lower sales of hemodynamic flow alteration devices products.
Key Developments
- In 2019, In a feasibility study done in Europe, Innovative Cardiovascular Solutions revealed the first successful clinical use of its next-generation embolic protection device, Emblok, in patients undergoing transcatheter aortic valve implantation (TAVI).
- In 2018, Claret Medical, Inc., a major firm known for creating Sentinel, a Cerebral Embolic Protection System, has been acquired by Boston Scientific Corporation.
Abbott Laboratories
Overview: Abbott Laboratories is a healthcare corporation and medical device based in Abbott Park, Illinois, United States. In 1888, Chicago physician Wallace Calvin Abbott created the company to develop well-known pharmaceuticals; now, it distributes medical devices, diagnostics, branded generic medicines, and nutritional supplements. In 2013, it separated its research-based pharmaceuticals business into AbbVie.
Product Portfolio:
Embolished NAV6TM: The Emboshield NAV6TM, Embolic Protection System, is indicated for use as a guidewire and embolic protection system to contain and remove embolic material (thrombus/debris) while performing angioplasty and stenting procedures in carotid arteries and atherectomy in lower extremity arteries, either alone or in conjunction with PTA and stenting. The artery diameter at the location of the Filtration Element should be between 2.5 and 7.0 mm.
